According to the latest annual report, BD Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. Primary customers include hospitals and clinics, governmental and nonprofit public health agencies, and healthcare workers to name a few. This division is organized into diabetes care, medication and procedural solutions, medication management solutions, and pharmaceutical systems.
BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers. This division is organized into preanalytical systems, diagnostic systems, and biosciences.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Becton Dickinson income statement, its balance sheet, and the statement of cash flows. Potential Becton Dickinson investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Becton Dickinson investors may use each financial statement separately, they are all related. The changes in Becton Dickinson's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Becton Dickinson's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Becton Dickinson
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Becton Dickinson performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Becton Dickinson shares is the value that is considered the true value of the share. If
the intrinsic value of Becton is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Becton Dickinson. Please read more on our
fundamental analysis page.
How effective is Becton Dickinson in utilizing its assets?
Becton Dickinson and reports assets on its Balance Sheet. It represents the amount of Becton resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Becton Dickinson aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Health Care Equipment & Supplies space. To get a better handle on how balance sheet or income statements item affect Becton volatility, please check the breakdown of all its
fundamentals.
Are Becton Dickinson Earnings Expected to grow?
The
future earnings power of Becton Dickinson involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Becton Dickinson factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Becton Dickinson
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Becton
expected earnings.
And What about dividends?
A dividend is the distribution of a portion of Becton Dickinson earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Becton Dickinson dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Becton one year expected dividend income is about USD2.11 per share.
At this time, Becton Dickinson's
Dividends Paid is fairly stable compared to the past year.
Dividend Paid And Capex Coverage Ratio is likely to rise to 11.77 in 2024, whereas
Dividend Yield is likely to drop 0.01 in 2024.
Investing in dividend-paying stocks, such as Becton Dickinson and is one of the few strategies that are good for long-term investment. Ex-dividend dates are significant because investors in Becton Dickinson must own a stock before its ex-dividend date to receive its next dividend.
This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Becton Dickinson. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.
Becton Dickinson Gross Profit
Becton Dickinson Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Becton Dickinson previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Becton Dickinson Gross Profit growth over the last 10 years. Please check Becton Dickinson's
gross profit and other
fundamental indicators for more details.
Is Becton Dickinson valued reasonably by the market?
Becton, Dickinson and Company operates within the healthcare sector and the medical instruments and supplies industry. Price to Earnings (P/E) ratio is used as a broad way to compare value against the industry, as well as competitors. BDX currently has a trailing twelve-month (ttm) P/E ratio of 84.48, compared to the industry P/E ratio of 25.26. Forward P/E is projected at 16.71, bringing the ratio back to normalized levels. Current P/E levels suggest investors are forecasting earnings growth in the next year or two. This is likely due to the finalized acquisition of C.R. Bard, Inc. on the 29th of December 2017.
Becton, Dickinson and Company face many risks due to the nature of their operations. One of the risks include the competitive nature of the medical technology industry. Being a global company increases competition across all of their product lines. Also, the technology involved continues to change at a rapid pace. To retain their competitive nature, continued focus on research and development is a must.
Risks associated with the C.R. Bard, Inc. acquisition include the combining of two companies may prove to be more difficult, costly, or time consuming as originally planned. As with any company, especially a large international one, they are likely to face speed bumps, slowing the merging process.
Becton, Dickinson and Company continues to provide value to shareholders via appreciation of stock price and dividends, which are generated through continued growth. Many large financial institutions agree by holding the company at their current recommendation or increasing it as Citigroup did January 5th of 2018. Continued monitoring of this company is necessary and continued proof of product development and diversification are crucial for future success.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Nathan Young is a Senior Member of Macroaxis Editorial Board - US Equity Analysis. With years of experience in the financial sector, Nathan brings a diverse base of knowledge. Specifically, he has in-depth understanding of application of technical and fundamental analysis across different equity instruments. Utilizing SEC filings and technical indicators, Nathan provides a reputable analysis of companies trading in the United States.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nathan Young do not own shares of Becton Dickinson and. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com